Ramírez-Tapia Y, Silva-Blas L, Cebrián-García R, Jiménez-Ponce F

Language: Spanish
References: 21
Page: 10-14
PDF size: 290.56 Kb.

ABSTRACT

Introduction: dexmedetomidine is and useful adjuvant agent in the perioperative anesthetic management associated to nasal administration with minimum adverse effects. Material and methods: a randomized, controlled, double blind, clinical trial was carried out in elective patients undergoing laparoscopic cholecystectomy with general anesthesia. Aim of this study was to compare the postoperative analgesic effect through visual analogue scale (VAS) and the perioperative opioid consumption. Dexmedetomidine was administrated intranasally (1 μg/kg dose) versus placebo. Statistical analysis was realized through student t and Fisher Test. Results: 54 patients were randomized in two groups: dexmedetomidine vs control. Not significant differences were found between both groups in demographic variables but 81.5% were women. Mean of VAS score at 60 minutes was significantly inferior (2.89 ± 1.9) versus control group (5.78 ± 2.3) (p < 0.0001). Mean of opioids consumption in dexmedetomidine group (0.424 ± 0.074 μg/h) was significant minor of control group (0.697 ± 0.136 μg/h) (p < 0.0001). Size effect through Cohen test was 250%. Conclusion: statistically decrease in VAS and in opioid consumption was observed using dexmedetomidine nasally in laparoscopic cholecystectomy.

REFERENCES

1. Alfonso J, Reis F. Dexmedetomidine: current roll in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62:118-133.

2. Mato M, Pérez A, Otero J, Torres LM. Dexmedetomidine, a promising drug. Rev Esp Anestesiol Reanim. 2002;49:407-420.

3. Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007;105:374-380.

4. Nesek-Adam V, Mrsic V, Smiljanic A. Specific Anesthetic Management in laparoscopic surgery. Lijec Vjesn. 2004;126:22-25.

5. Grewal A. Dexmedetomidine: a new avenue. J Anaesthesiol Clin Pharmacol. 2011;27:297-302.

6. Tang C, Xia Z. Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic. J Pain Res. 2017;10:1899-1904.

7. Lirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, et al. Bioavailability of dexmedetomidine after intranasal administration. Eur J Clin Pharmacol. 2011;67:825-831.

8. Pérez-Guillé MG, Toledo-López A, Rivera-Espinoza L, Alemon-Medina R, Murata C, Lares-Asseff I, et al. Population pharmacokinetics and pharmacodynamics of dexmedetomidine in children undergoing ambulatory surgery. Anesth Anal. 2018;123:716-723.

9. Li A, Yuen VM, Goulay-Dufay S, Sheng Y, Standing JF, Kwok PCL, et al. Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine. Br J Anaesth. 2018;120:960-968.

10. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56:893-913. doi: 10.1007/s40262-017-0507-7.

11. Liu HC, Lian QQ, Wu FF, Wang CY, Sun W, Zheng LD, et al. Population pharmacokinetics of dexmedetomidine after short intravenous infusion in Chinese children. Eur J Drug Metab Pharmacokinet. 2017;42:201-211.

12. Bielka K, Kuchyn L, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during Laparoscopic Cholecystectomy: a randomized controlled study. BMC Anesthesiol. 2018;18:44. doi: 10.1186/s12871-018-0508-6.

13. ParK JK, Cheong SH, Lee KM, Lim SH, Lee JH, Cho K, et al. Does dexmedetomidine reduce postoperative pain after laparoscopic cholecystectomy with multimodal analgesia? Korean J Anesthesiol. 2012;63:436-440. doi: 10.4097/kjae.2012.63.5.436.

14. Bhagat N, Yunus M, Karim HM, Hajong R, Bhattacharyya P, Sing M. Dexmedetomidine in attenuation of haemodynamic response and dose sparing effect on opioid and anaesthetic agents in patients undergoing laparoscopic cholecystectomy a randomized study. J Clin Diag Res. 2016;10:UC01-UC05. doi: 107860/JCDR/2016/21501.8815.

15. Yoo H, Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, et al. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. Eur J Clin Pharmacol. 2015;71:1197-1207. doi: 10.1007/s00228-015-1913-0.

16. Wang CY, Ihmsen H, Hu ZY, Chen J, Ye XF, Chen F, et al. Pharmacokinetics of intranasally administered dexmedetomidine in Chinese children. Front Pharmacol. 2019;10:756. doi: 10.3389/fphar.2019.00756.

17. Lirola T, Ihmsen H, Laitio R, Kentala E, Aantaa R, Kurvinen JP, et al. Population pharmacokinetics of dexmedetomidina during long-term sedation in intensive care patients. Br J Anaesth. 2012;108:460-468.

18. Vega R, Sepúlveda P, Quiroga M, Rodríguez G, Reyes C, Laporte A. Dexmedetomidina nasal en colecistectomía laparoscópica. Rev Chil Anestesia. 2008;37:143-163.

19. Tang C, Huang X, Kang F, Chai X, Wang S, Yin G, et al. Intranasal dexmedetomidine on stress hormones, inflammatory markers, and postoperative analgesia after functional endoscopic sinus surgery. Mediators Inflamm. 2015;2015:939431. doi: 10.1155/2015/939431.

20. Lu C, Zhang LM, Zhang Y, Ying Y, Li L, Xu L, et al. Intranasal dexmedetomidine as a sedative premedication for patients undergoing suspension laryngoscopy: a randomized double-blind study. PLoS One. 2016;11:e0154192. doi: 10.1371/journal.pone.0154192.

21. Wu X, Hang LH, Wang H, Shao DH, Xu YG, Cui W, et al. Intranasally administered adjunctive dexmedetomidine reduces perioperative anesthetic requirements in general anesthesia. Yonsei Med J. 2016;57:998-1005. doi: 10.3349/ymj.2016.57.4.998.